Mereo BioPharma
MREO
79 hedge funds and large institutions have $362M invested in Mereo BioPharma in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 27 reducing their positions, and 15 closing their positions.
60% more call options, than puts
Call options by funds: $2.8M | Put options by funds: $1.75M
31% more capital invested
Capital invested by funds: $277M → $362M (+$84.9M)
2.35% more ownership
Funds ownership: 11.98% → 14.33% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 80 → 79 (-1)
26% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$21.7M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$14.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$8.94M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.98M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$11.6M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.44M |
| 3 |
Morgan Stanley
New York
|
-$3.81M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.27M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.52M |
MREO Hedge Fund Activity: Q2 2024 in Review
79 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2024, worth a combined $362M — up 31% from $277M a quarter earlier.
Fund positioning in MREO was balanced in Q2 2024: 15 funds opened new positions, 15 closed out, 20 added to existing stakes and 27 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $21.7M. The largest seller was Suvretta Capital Management, cutting an estimated $11.6M.
- 79 institutional investors held Mereo BioPharma (MREO) as of Q2 2024, down from 80 in Q1 2024.
- Funds reported $362M of Mereo BioPharma stock for Q2 2024, up 31% quarter-over-quarter.
- 15 funds opened new Mereo BioPharma positions in Q2 2024 and 15 closed out, a net change of 0 holders.
- The largest Mereo BioPharma buyer in Q2 2024 was Deerfield Management, an estimated $21.7M added.
- The largest Mereo BioPharma seller in Q2 2024 was Suvretta Capital Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2024.